Research output per year
Research output per year
Abstract
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the efficacy of linezolid when used as part of a second-line regimen for treating people with multidrug-resistant (MDR-) and extensively drug-resistant (XDR-) pulmonary tuberculosis (TB), and to assess the prevalence and severity of adverse events associated with linezolid use in this patient group.
To assess the efficacy of linezolid when used as part of a second-line regimen for treating people with multidrug-resistant (MDR-) and extensively drug-resistant (XDR-) pulmonary tuberculosis (TB), and to assess the prevalence and severity of adverse events associated with linezolid use in this patient group.
| Original language | English |
|---|---|
| Article number | CD012836 |
| Pages (from-to) | 1-9 |
| Number of pages | 9 |
| Journal | Cochrane Database of Systematic Reviews |
| Volume | 2017 |
| Issue number | 11 |
| DOIs | |
| Publication status | Published - 10 Nov 2017 |
Access to Document
Other files and links
Fingerprint
Dive into the research topics of 'Linezolid for drug-resistant tuberculosis'. Together they form a unique fingerprint.Research output
- 1 Review article
-
Linezolid for drug-resistant pulmonary tuberculosis
Singh, B., Cocker, D., Ryan, H. & Sloan, D. J., 20 Mar 2019, In: Cochrane Database of Systematic Reviews. 2019, 3, CD012836.Research output: Contribution to journal › Review article › peer-review
Open AccessFile